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Background: Blood-brain barrier disruption has been noted in animal models of Parkinson’s disease 27 
(PD) and forms the basis of the vascular hypothesis of neurodegeneration, yet clinical studies are 28 
lacking.  29 
Objective: To determine alterations in blood-brain barrier integrity in PD, with comparison to 30 
cerebrovascular disease. 31 
Methods: Dynamic contrast enhanced magnetic resonance images were collected from 49 PD 32 
patients, 15 control subjects with cerebrovascular disease (control positive CP) and 31 healthy 33 
control subjects (control negative CN), with all groups matched for age. Quantitative maps of the 34 
contrast-agent transfer coefficient across the blood-brain barrier (K
trans
) and plasma volume (vp) were 35 
produced using Patlak analysis. Differences in K
trans
 and vp were assessed with voxel-based analysis 36 
as well as in regions associated with PD pathophysiology. In addition, the volume of white matter 37 
lesions (WML) was obtained from T2-weighted fluid attenuation inversion recovery (FLAIR) images.  38 
Results:  Higher K
trans
, reflecting higher blood-brain barrier leakage, was found in the PD group than 39 
in the CN group using voxel-based analysis; differences were most prominent in the posterior white 40 
matter regions. Region of interest analysis confirmed K
trans
 to be significantly higher in PD than in 41 
CN, predominantly driven by differences in the substantia nigra, normal-appearing white matter, 42 
WML and the posterior cortex. WML volume was significantly higher in PD compared to CN. K
trans
 43 
values and white matter lesion volume were similar in PD and CP, suggesting a similar burden of 44 
cerebrovascular disease despite lower cardiovascular risk factors.   45 
Conclusion: These results show blood-brain barrier disruption in PD. 46 
Abbreviations:  47 
ANOVA – analysis of variance, BBB – blood-brain barrier,  CA – caudate, CN – control negative,  48 
CP – control positive, CSF – cerebral spinal fluid, DCE-MRI – dynamic contrast enhanced magnetic 49 
resonance imaging, FLAIR – fluid attenuation inversion recovery, FC – frontal cortex, FWE – family 50 
wise error,  Hct – haematocrit,  K
trans
 – contrast agent endothelial transfer coefficient,  LEDD – 51 
Levodopa equivalent daily dose, MNI – Montreal Neurological Institute, MoCA – Montreal 52 
cognitive assessment, NAWM – normal appearing white matter, NHS – National Health Service, P – 53 
pallidum, PET – positron emission tomography, PC – posterior cortices, PD – Parkinson’s disease, 54 
PU – putamen, ROI – region of interest, SN – substantia nigra, SNpc – substantia nigra pars 55 
compacta, SPM – statistical parametric mapping, T1-FFE – T1 fast field echo, TE – echo time, 3 T – 56 
3 tesla, TR – repetition time, UPDRS – Unified Parkinson’s Disease Rating Scale, vp – plasma 57 
volume,  VEGF – vascular endothelial growth factor, WML – white matter lesion. 58 
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1 Introduction 60 
The blood-brain barrier (BBB) consists of highly specialised, metabolically active cells forming a 61 
selectively permeable, highly resistant barrier to diffusion of blood products (1). It is closely coupled 62 
with glial cells (i.e. pericytes, microglia, oligodendroglia, and astrocyte end-feet), all in close 63 
proximity to a neuron; collectively termed the neurovascular unit (2, 3). Normal functioning of the 64 
neurovascular unit ensures healthy function of the BBB and adequate cerebral blood flow, it also 65 
maintains the neuronal ‘milieu’ which is required for proper functioning of neuronal circuits and 66 
ensures the metabolic needs of the neurons are met (4, 5). In the neurovascular unit, BBB 67 
permeability and cerebral blood flow are mainly controlled by endothelial cells, smooth muscle cells 68 
and pericytes; damage to which have been associated with accumulation of neurotoxins and hypoxia 69 
leading to neuronal injury and loss (6, 7). 70 
Neurodegeneration is now understood to be the consequence of multiple factors acting and 71 
interacting over time to lead to neuronal dysfunction and death (8-10). Neurovascular unit 72 
dysfunction, unsurprisingly, contributes to neuronal dysfunction and death; this forms the basis of the 73 
‘vascular model of neurodegeneration’ (4, 11-15). The two pillars of this model are hypoperfusion 74 
and BBB disruption, both contributing to the vicious circle of neuronal loss. Studies particularly in 75 
the preclinical setting, suggest microvascular pathology and hypoperfusion occurs in the context of 76 
neurodegenerative diseases (4, 16-19). In addition studies in Parkinson’s disease (PD) have revealed 77 
vascular remodeling, altered vasculature and abnormal angiogenesis (20-26).  78 
Understanding of the pathogenesis of PD centres around the selective and progressive loss of 79 
dopaminergic neurons in the substantia nigra pars compacta (SNpc) and its connections with other 80 
basal ganglia structures. BBB disruption contributing to neurodegeneration in the SNpc has been 81 
reported in PD in animal studies (26-28). In humans, a relatively small PET study in PD patients 82 
revealed dysfunction of the BBB transporter system (29). A histological study revealed significantly 83 
increased permeability of the BBB in the post commissural putamen of PD patients (30). Thus the 84 
areas implicated in PD pathology have been shown to demonstrate BBB disruption, yet studies 85 
remain few and predominantly in animal models.  86 
Many studies describe hypoperfusion in the posterior cortices in PD, in particular in the posterior 87 
parieto-occipital cortex, precuneus and cuneus and temporal regions with variable patterns in the 88 
frontal lobe (31-35). The extent to which BBB disruption impacts perfusion and vice versa 89 
(hypoperfusion influencing BBB disruption) is poorly understood. However, both occur at the 90 
microvascular level and may be linked. If this is the case, this then suggests that alterations in BBB 91 
may also be expected in these posterior regions as well as in regions implicated in PD pathology such 92 
as the basal ganglia, where neuronal loss and loss of nigrostriatal projections occurs. 93 
Advances in neuroimaging techniques, in particular quantitative MRI techniques such as arterial spin 94 
labelling and dynamic contrast enhanced MRI (DCE-MRI), have paved the way for studies of the 95 
microcirculation in the clinical setting, with DCE-MRI specifically probing BBB integrity (36). 96 
Previously applied to measure BBB disruption in tumours, multiple sclerosis and acute ischemic 97 
stroke, recent applications have used this technique to probe more subtle and chronic BBB 98 
disruption. Studies include small vessel disease (37), Alzheimer’s disease (38), mild cognitive 99 
impairment and normal ageing (39), vascular cognitive impairment (40) and diabetes (41) ; its value 100 
in these settings has been systematically reviewed (42). To our knowledge there is no published work 101 
on DCE-MRI measures in PD. 102 
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We used DCE-MRI to investigate regional alterations in BBB permeability in the context of PD. PD 103 
was compared with a control group with known cerebrovascular disease (control positive (CP)) and a 104 
control group without known cerebrovascular disease or PD (control negative (CN)). Our aim was to 105 
investigate whether potential changes are simply attributable to co-existing cerebrovascular disease in 106 
an aging population or if a pattern of BBB alterations specific to PD is revealed. Inclusion of the CP 107 
group allows us to do this by comparing the pattern of BBB disruption in the PD and CP groups with 108 
reference to the burden of cerebrovascular disease in each group, defined by white matter lesion 109 
(WML) volume as an accepted surrogate marker of small vessel disease. We hypothesized that BBB 110 
disruption in PD would occur in the basal ganglia structures due to the pathophysiology of PD being 111 
centred around selective and progressive loss of dopaminergic neurons in the SNpc and nigrostriatal 112 
pathways. Therefore, based on the vascular hypothesis of neurodegeneration, these areas should 113 
display BBB disruption. We also expected BBB disruption to occur in posterior and frontal cortices 114 
given that hypoperfusion, which potentially impacts BBB function, has been noted in these regions in 115 
PD. Finally, as BBB alterations in cerebrovascular disease have been found within WML and in the 116 
normal-appearing white matter (NAWM) (43) we also considered alterations in these regions. Hence 117 
we investigated BBB changes in basal ganglia, posterior and frontal cortex regions, NAWM and 118 
WML, along with a more exploratory voxel-wise analysis across the entire brain.  119 
 120 
2. Materials and Methods 121 
2.1 Approvals, recruitment, eligibility and consent 122 
Relevant approvals were obtained including NHS ethical approval (North West – Preston Research 123 
Ethics Committee), research governance and local university approvals. PD patients were recruited 124 
from Lancashire Teaching Hospitals NHS Foundation Trust and Salford Royal NHS Foundation 125 
Trust.  Eligibility criteria for PD participants were a clinical diagnosis of PD fulfilling UK 126 
Parkinson’s disease society brain bank criteria (www.ncbi.nlm.nih.gov/projects) without known 127 
clinical cerebrovascular disease (no history of transient ischaemic attack or stroke) or dementia (44). 128 
Participants with cerebrovascular disease were recruited from patients attending Lancashire Teaching 129 
Hospitals with a clinical diagnosis of stroke or transient ischaemic attack within the previous 2 years 130 
(and at least 3 months prior to participation) supported by relevant brain imaging (control positives, 131 
CP). Controls without a history of either PD or clinical cerebrovascular disease were also recruited 132 
from the local community (control negatives, CN). All groups were matched for age. All participants 133 
were required to provide written informed consent and had capacity to do so.  134 
2.2 Clinical assessments  135 
PD assessment included  the Unified Parkinson’s Disease Rating Scale (UPDRS) 136 
(www.mdvu.org/library/ratingscales/pd/updrs.pdf) during the scan visit. Disease severity was 137 
measured using the Hoehn and Yahr rating scale (45). No alterations were made to the participants’ 138 
medications for the study protocol. Routine clinical baseline data were also recorded and the 139 
levodopa equivalent daily dose (LEDD) calculated (46). A battery of clinical scales was also 140 
administered, including the Montreal Cognitive Assessment (MoCA) (www.MoCAtest.org) to 141 
measure cognition. Demographics and clinical data were compared between PD and control 142 
participants using unpaired Student’s t-test for continuous variables or Fisher’s exact test for 143 
categorical variables with p-value set at < 0.05.  144 
 145 
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2.3 MRI protocol 146 
Participants were scanned on one of two systems running the same software version: a 3.0 T Philips 147 
Achieva scanner with an 8 channel head coil at Salford Royal Hospital or a separate 3.0 T Philips 148 
Achieva scanner with a 32 channel head coil at the Manchester Clinical Research Facility. 149 
Involuntary movements in participants were minimised using padding within the head coil.  150 
Both scanners ran an identical MRI protocol. A DCE-MRI dynamic series of 160 3D T1-weighted 151 
images (T1 Fast Field Echo; T1-FFE) were acquired with a temporal resolution of 7.6 seconds, spatial 152 
resolution of 1.5 x 1.5 x 4 mm, and total duration of approximately 20 minutes. On the 8th dynamic, 153 
a gadolinium-based contrast agent (Dotarem) bolus was administered using a power injector. The 154 
volume administered was proportional to the weight of the subject with a dose of 0.1 mmol/kg.  155 
Prior to the dynamic scan, a series of additional 3D T1-FFE images were acquired at 3 flip angles (2, 156 
5 and 10 degrees) in order to calculate a pre-contrast T1 map using the variable flip angle method. A 157 
B1 map was also collected in order to correct for B1 field inhomogeneities.  158 
In addition, a 1 mm isotropic 3D T1-weighted image and a T2-weighted FLAIR image were acquired. 159 
Please see supplementary material for full details of acquisition parameters.  160 
2.4 MRI analysis 161 
2.4.1 White matter lesion volume estimation 162 
WML volume was calculated as an established marker of small vessel disease (47). WML volume 163 
was estimated using the lesion segmentation toolbox (48) in SPM8 using both T2-weighted FLAIR 164 
images and T1-weighted images as inputs. A threshold of 0.3 was chosen as it gave the most accurate 165 
estimates in a sub-study comparing WML volume estimates from the lesion segmentation toolbox 166 
with those from semi-automated lesion-growing methods on a subset of the data (n = 51, including 167 
representation from all groups, unpublished) (https://www.statistical-modelling.de/lst.html). WML 168 
volumes were positively skewed and were therefore cube-root transformed as is commonly done (49) 169 
before group comparisons using un-paired t-tests.  170 
 171 
2.4.2 DCE analysis 172 
The dynamic series of 160 images were first corrected for motion using the ‘realignment’ option in 173 
SPM12 (www.fil.ion.ucl.ac.uk/spm), which aligned all DCE-MRI images to the first image in the 174 
time-series. A vascular input function was derived from the sagittal sinus (50), which was delineated 175 
using MRIcro on the final image of the motion-corrected dynamic time series. Regions of 176 
approximately 50 voxels were selected. A voxel-by-voxel fit of the dynamic data for both the 177 
contrast agent transfer coefficient (K
trans
) and plasma volume (vp) was performed using the uptake or 178 
‘Patlak’ model assuming unidirectional transport of the tracer from the blood plasma to the 179 
extravascular, extracellular space. Further details regarding DCE-MRI analysis can be found in 180 
Supplementary Material. 181 
Mean images of K
trans
 and vp in each of the three groups were created following spatial smoothing 182 
using a 3D 3 mm full-width-half-maximum kernel in and visually inspected for differences. Voxel-183 
wise analysis was performed using the SPM12 PET toolbox to determine regional differences in K
trans
 184 
and vp between the groups. K
trans
 and vp maps were co-registered to the high resolution 3D T1-185 
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weighted image and then normalized to Montreal Neurological Institute (MNI) space. The 186 
normalised K
trans
 and vp maps were spatially smoothed using an 8 mm full-width-half-maximum 187 
kernel. Voxel-wise comparisons of K
trans
 and vp between the groups were performed, without 188 
intensity normalisation, using a two-sample unpaired t-test (unequal variances). Group comparisons 189 
were performed between: CN and PD, CP and PD and CP and CN. Regions were considered to show 190 
significant group differences at a voxel-level threshold of p < 0.001 uncorrected, and a minimum 191 
cluster size of 50 voxels, masked to the intra-cranial volume. Further analysis using family-wise error 192 
(FWE) correction for multiple comparisons at the cluster level was performed. The MNI coordinates 193 
were used to identify regions showing group differences using xjview V 8.14 194 
(http://www.alivelearn.net/xjview8/).   195 
Group differences in K
trans
 and vp were also assessed in regions of interest (ROI) including the basal 196 
ganglia, frontal and posterior cortices, WML and NAWM. WML regions were obtained using the co-197 
registered binary lesion masks from the lesion segmentation (see section 2.4.1) and care was taken to 198 
remove regions of WML from all other ROIs. The caudate (CA), putamen (PU) and pallidum (P) 199 
regions were obtained from MNI atlases (51, 52) . The substantia nigra (SN) region was manually 200 
drawn on the T2-weighted template image from SPM by an experienced researcher. Frontal and 201 
selected posterior cortical regions were also defined (in keeping with regions of hypoperfusion in 202 
other studies) (30, 33, 34, 53) using a combination of regions from the automatic anatomical labelling 203 
atlas (51). The frontal region consisted of superior and middle frontal gyri and the posterior region of 204 
precuneus, cuneus, lingual, superior and middle occipital gyri. Finally, NAWM was also selected, 205 
defined using the mask from the segmentation of the co-registered T1-weighted image, in order to 206 
determine the significance of any diffuse differences between the groups. Figure 1 depicts the 207 
location of these ROIs.   Mean K
trans
 and vp values were extracted from each of these regions for each 208 
subject. Repeated measures ANOVA was performed with factors ‘group’ and ‘region’ to determine 209 
any significant difference in K
trans
 and vp between the groups with ‘subject’ included as a random 210 
effect. A second ANOVA was performed with the addition of age, gender and the cube-root of WML 211 
volume as co-variates to determine if these factors could explain any variance in K
trans
 and vp. Where 212 
significant group differences were found, post-hoc t-tests were performed with Bonferroni correction 213 
where stated. Statistical analyses were conducted using R 3.6.0 (R Core Team, 2019).  214 
2.4.3 Correlation with cognitive and clinical parameters  215 
Any association between the DCE-MRI parameters and cognitive deficit, medication and disease 216 
severity within the PD group was evaluated with a linear mixed effects model and ANOVA. Region 217 
(as a factor), MoCA score, LEDD dose and UPDRS score (as continuous variables) and their 218 
interaction with region were modelled as fixed effects, and subject was set as a random effect. Where 219 
significant interactions with region were found, the fixed effects t-tests and corresponding p values 220 
for each region were considered, calculated using Satterthwaite’s approximation in the lmerTest 221 
package (54) in R 3.6.0 (R Core Team, 2019). 222 
2.5 Data Availability 223 
Data including images, imaging metrics and participant metadata are available on request. Please 224 
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3. Results 228 
Fifty-one PD patients were recruited, 17 CP subjects with cerebrovascular disease (13 with ischemic 229 
stroke, 4 with single or multiple transient ischaemic attacks; mean time since symptom onset and 230 
where applicable most recent known transient ischaemic attack = 1.1 ± 0.7 years) and 34 CN 231 
subjects. Twenty-eight participants were scanned at Salford Royal Hospital and 74 participants at the 232 
Manchester Clinical Research Facility (37 PD, 20 CN and 17 CP). 233 
Data from 7 participants could not be analysed due to i) participants not tolerating the complete scan 234 
procedure (n=2) ii) failure of the contrast agent injection (n=3), resulting in either absent, very low or 235 
very distorted vascular input function and iii) non-physiological values of plasma volume (n=2); 236 
leaving data from 95 participants (49 PD, 31 CN, 15 CP). Summary demographic information from 237 
these patients is given in Table 1, along with the WML volume measurements. There were no 238 
significant differences in age between the groups. As expected the CP group had more 239 
cerebrovascular risk factors than either the PD or CN groups but there was no difference in risk 240 
factors between the PD and CN groups. WML volume was significantly higher in the PD group than 241 
the CN group, suggesting that, although vascular risk factors are similar, there was increased 242 
microvascular pathology in the PD group. WML volume was also higher in the CP group that the CN 243 
group, as expected, but not significantly different from the PD group. The PD group had significantly 244 
lower MoCA score compared to the CN group, but was not significantly different from the CP group. 245 
It is noted that there are significant gender differences between the PD and CN groups, which is 246 
addressed directly in a sub-analysis (see Supplementary Materials).  247 
3.1 Voxel-wise analysis 248 
Figure 2 shows mean images of K
trans
 and vp in the three groups. It can be seen that K
trans
 is generally 249 
higher in PD than in the control groups. The vp maps look similar between the PD and CN group, but 250 
the CP group has noticeably lower vp. 251 
The voxel-wise comparisons revealed significantly higher K
trans
 in the PD group than in the CN group 252 
(Figure 3 and Table S1) in regions including white matter regions of the precuneus bilaterally. Only 253 
the largest region in the right pre-cuneus survived cluster-level FWE correction. There were no 254 
regions of significantly lower K
trans
 in PD than in CN. K
trans
 was also significantly higher in the PD 255 
group than in the CP group in one region of white matter in the right temporal lobe (Table S2). 256 
Significantly higher K
trans
 wass also seen in the CP group than in the CN group (Table S3), in the mid 257 
cingulum and R cerebellumAside from for the PD vs CN comparison, none of these regions survived 258 
the cluster-level FWE correction.  259 
CP showed regions of significantly lower vp than CN (Table S4) and PD (Table S5) in white matter 260 
regions of the left and right temporal lobes. No significant voxel-wise differences in vp were seen for 261 
PD vs CN. 262 
3.2 ROI Analysis 263 
Figure 4  shows group mean regional values for K
trans
 and vp. There was a significant effect of group 264 
(F = 3.3, p = 0.04) and region (F = 54.1, p < 0.0001) on K
trans
 with post-hoc tests showing K
trans
 to be 265 
significantly higher in PD than in CN (p=0.03, Bonferroni corrected) and no significant differences 266 
between the other two pairwise comparisons. The NAWM, posterior cortex and SN show elevated  267 
K
trans
 in PD compared to CN when considering differences on a region-by-region basis (p<0.05, 268 
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uncorrected). K
trans
 is also higher within the WML in PD in comparison to CN. A second ANOVA 269 
with WML volume, age and gender included as covariates showed a similar effect of group (F = 3.9, 270 
p=0.02) and region (F = 54.1, p<0.0001 ) and no significant effect of WML volume (F=1.0. p=0.3), 271 
age (F=1.1, p=0.3) or gender (F=0.1, p=0.8). Post-hoc tests again showed K
trans
 to be significantly 272 
higher in PD than in CN (p=0.02, Bonferroni corrected). 273 
There was a significant effect of region (F=90.0, p < 0.0001) but not group (F = 1.1, p = 0.3) on vp. 274 
The second ANOVA with WML volume, age and gender included as covariates showed a similar 275 
result with an impact of region (F = 90.0, p<0.0001) but not group (F = 1.1, p=0.3) on vp and no 276 
significant effect of WML volume (F=0.1. p=0.8), age (F=2.2, p=0.1) or gender (F=0.2, p=0.6). 277 
To check that differences were not driven by the differences in gender-matching or by the use of two 278 
scanners, the regional analysis was repeated with gender-matched groups and with data from only 279 
one scanner. Broadly the same regional and group effects were seen for both K
trans
 and vp (see 280 
supplementary materials). 281 
3.3 Correlation with cognitive and clinical parameters 282 
Table 2 summaries the ANOVA findings evaluating the impact of cognitive deficit (MoCA score), 283 
medication (LEDD dose) and disease severity (UPDRS score) on the DCE-MRI parameters within 284 
the PD group. There are no significant associations between these parameters and K
trans
. In particular, 285 
LEDD dose was not associated with K
trans 
suggesting that the increased BBB leakage seen in the PD 286 
group is not a consequence of medication. A significant effect of LEDD dose on vp was found with 287 
higher LEDD dose associated with higher vp.   288 
 289 
4. Discussion 290 
The aim of this study was to determine alterations in BBB permeability in PD, by comparison with 291 
controls, and to investigate whether potential changes are simply attributable to co-existing 292 
cerebrovascular disease in an aging population or if a pattern of BBB alteration specific to PD is 293 
revealed. The results show higher K
trans
, reflecting higher BBB leakage, in PD than in CN (Figure 2 294 
and 3 and Table S1), with a somewhat different spatial pattern to the differences seen between 295 
individuals with known cerebrovascular disease (CP) and CN (Table S3). Direct comparison of PD 296 
and CP shows higher K
trans
 for PD in the white matter of the right temporal lobe (Table S2). Blood 297 
plasma volume, vp, is similar in PD and CN, with some evidence of lower vp in the CP group (Table 298 
S4 and S5 and Figure 4).  Collectively these data demonstrate BBB disruption in PD can be detected 299 
in the clinical setting in keeping with evidence from studies in animal models and post mortem 300 
human brain. The K
trans
 values (Figure 4) are within the wide range of published values which seem 301 
dependent on the specific acquisition and analysis methods and contrast agents used (55). A study 302 
using the same contrast agent and similar method shows very comparable values (56).   303 
Both the voxel-based and the ROI analysis showed higher K
trans
 in PD when compared with CN. 304 
These results are in keeping with several studies showing altered components of the BBB in PD (27, 305 
57-59) such as loss of capillaries, an alteration in the capillary caliber and thickened basement 306 
membrane (making the BBB less competent) (16). Our voxel-based analysis approach allows a whole 307 
brain view of BBB dysfunction, and, in the whole brain maps, we see a fairly diffuse pattern of BBB 308 
disruption in PD, compared to CN. K
trans
 differences only reach statistical significance in posterior 309 
regions; however, given the requirement for multiple comparisons correction, it would likely require 310 
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a much larger study for smaller brain regions such as basal ganglia nuclei to survive the statistical 311 
threshold. The ROI approach focused on areas expected to display disease pathology based on our 312 
understanding of the pathophysiology of PD. It revealed K
trans
 to be generally higher in the PD group 313 
than in the CN group. Considering the magnitude and significance of regional K
trans
 differences 314 
between PD and CN (Figure 4), this is driven mainly by differences in SN, NAWM, WML and the 315 
posterior cortex. Alterations in SN and posterior cortex are in keeping with BBB breakdown playing 316 




 in posterior cortical regions in PD is particularly noteworthy as these are the 319 
same regions that display hypoperfusion (33, 34, 53, 60) i.e. the results strengthen the argument of a 320 
link between BBB leakage and hypoperfusion.  Hypoperfusion has been attributed to altered 321 
vasculature (string vessels, shorter/loss of capillaries, tortuous vessels), which can hinder normal 322 
BBB function (25, 28, 30, 61). BBB disruption has been attributed to alterations in key components 323 
such as tight junctions, potentially caused by pro-inflammatory cytokines and altered vascular 324 
endothelial growth factor (VEGF) (62-64). Interestingly a study using  albumin (mg/L)/plasma 325 
albumin (g/L) ratio in the cerebral spinal fluid (CSF) to measure BBB dysfunction, revealed  326 
increased BBB dysfunction in PD compared to controls which was associated with increased CSF 327 
biomarkers of angiogenesis (e.g. VEGF) (22).These substances can also alter perfusion, with 328 
enhanced angiogenesis resulting in abnormal vascular permeability in PD. Future longitudinal 329 
imaging studies will be important to understand whether hypoperfusion leads to altered BBB 330 
function, or vice versa, or in fact whether BBB and perfusion changes have a common cause, for 331 
example, inflammation. Furthermore, it will be important to determine what downstream effects 332 
these microvascular changes may have on neuronal loss. We did not observe any statistically 333 
significant differences in K
trans
 between CP and CN unlike other studies which have reported elevated 334 
K
trans
 post-stroke (43). However, the small sample size and high heterogeneity of the CP group may 335 
have contributed to this. 336 
WML have been used as a surrogate marker of SVD (65). We find higher WML volume in the PD 337 
group than the CN group despite the fact the groups have no significant differences in cardiovascular 338 
risk factors. Previous studies of WML in PD however show mixed results (66, 67). To investigate 339 
whether the WML volume was driving the K
trans
 group differences, we used ANOVA with WML 340 
volume, age, and gender as co-variates and found that there was no significant association between 341 
WML volume (or age or gender) and K
trans
. The main finding of higher K
trans
 in the PD group than 342 
CN was maintained.  Recent work has tried to understand the link between BBB dysfunction and 343 
WML revealing a continuum of BBB disruption leading to myelin loss and fibrinogen accumulation 344 
resulting in WML formation (68-70).  Indeed NAWM (particularly that surrounding the WML) has 345 
been shown to have increased BBB leakage suggesting BBB disruption can precede WML formation  346 
(43). We do not find a significant association between WML volume and K
trans
, which alongside the 347 
higher K
trans
 in NAWM in the PD group compared to CN, supports this notion that BBB disruption is 348 
diffuse throughout the white matter and perhaps precedes WML formation. It is interesting to note 349 
that, within the lesions, K
trans
 is significantly higher in the PD group than in the CN group suggesting 350 
more severe underlying pathology. 351 
Our measurements of blood plasma volume, vp are not significantly different between PD and 352 
healthy controls, which may seem contradictory to the well-reported hypoperfusion in PD, given that 353 
blood volume and perfusion are closely related. However, blood flow also depends on the blood 354 
velocity within the capillaries which may underlie the observed differences. Indeed, we have 355 
previously found significantly prolonged arterial transit time in posterior brain regions in PD, 356 
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suggesting lower blood velocity (53). Furthermore, vp estimation may also be affected by the rate of 357 
trans-endothelial water exchange leading to possible underestimation of vp in the CN group in 358 
comparison to the PD group due to the relatively more intact BBB, potentially contributing to the 359 
lack of group difference seen. As the K
trans
 and vp patterns differed between CP and PD this would 360 
suggest that the BBB alterations do not simply occur due to co-existing cerebrovascular disease 361 
(indeed PD patients with known cerebrovascular disease were not included in the study and the PD 362 
group had significantly fewer cerebrovascular risk factors) but plays an independent role in PD 363 
pathophysiology. Together with the increased WML volume in the PD group, this supports the 364 
hypothesis that microvascular pathology occurs in PD. 365 
We explored the impact of cognitive deficit (MoCA score), medication (LEDD dose) and disease 366 
severity (UPDRS score) on K
trans
 and vp within the PD group. LEDD dose was associated with higher 367 
vp, which is in keeping with studies that suggest L-dopa increases blood flow in certain regions (71, 368 
72). There were no significant associations between any parameter and K
trans
 and we conclude that 369 
the K
trans 
differences between the PD and CN groups are not driven by the differences in MoCA score 370 
or by levodopa medications.  371 
One limitation of this study is the significant gender imbalance between the PD and CN groups 372 
(Table 1) with relatively more men in the PD group. However, we do not believe this compromises 373 
our findings as there are no reports of gender differences in K
trans
 values, and secondary analysis of 374 
our own data shows consistent findings in a gender-matched sub-group (Supplementary Materials). 375 
Likewise we collected data on two different scanners which may have influenced the results; 376 
however secondary analysis shows consistent findings in findings from a single scanner 377 
(Supplementary Materials). We interpret the higher K
trans
 in PD as relating to higher endothelial 378 
leakage, but note that K
trans
 is also affected by cerebral blood flow. However cerebral blood flow is 379 
lower than normal in posterior regions in PD (27, 29, 30, 46) which would lead to lower K
trans
, and 380 
yet we see higher K
trans
 in the PD group, implying that the differences are not due to blood flow 381 
differences. 382 
In conclusion, this study has shown subtle BBB disruption in PD, in key regions implicated in the 383 
pathophysiology including the substantia nigra, white matter and posterior cortical regions. Further 384 
research is needed, including longitudinal clinical imaging studies combining neuronal, metabolic 385 
and vascular measurements to better understand disease mechanisms and so identify potential 386 
therapeutic targets in PD. 387 
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Tables 594 
Table 1: Demographics and clinical and radiological characteristics of the study group 595 
 596 
AF: atrial fibrillation; CN: control negative; CP: control positive; CV: cardiovascular; DM: diabetes mellitus; FH of CVD: family history of 597 
cardiovascular disease; Hyperchol.: hypercholextrolaemia; IHD: ischaemic heart disease;  LEDD: levodopa equivalent daily dose; MoCA: 598 
Montreal Cognitive Assessment; RF: risk factors; PD: Parkinson’s disease; TD: tremor dominant;  UPDRS 111: unified Parkinson’s 599 








 CN (n=31) CP (n=15) PD (n=49) p value  
PD v CN 
p value  
PD v CP 
p value  
CP v CN 
n (F:M) 16:15 4:11 12:37 0.01 0.25 0.07 
Age (years):  
mean (range) 
66.4 (52-81) 69.1 (53-84) 68.9 (52-85) 0.23 0.84 0.26 
No. of cardiovascular risk 
factors: mean (SD) 
1.52 (1.12) 2.93 (1.16) 1.72 (1.52) 0.55 0.002 <0.0001 
Cardiovascular  Risk 
Factors  (% of group): 
Hypertension 
Diabetes mellitus  
FH of CVD 
Smoker 
Hypercholesterolaemia  
























































Disease Duration (years): 
mean (SD) 
N/A 1.1  (0.77) 7.2 (4.45) N/A N/A N/A 
Hoehn & Yahr Score:  
mean (SD) 
N/A N/A 2.60 (0.09) N/A N/A N/A 
UPDRS Score: 
mean (SD) 
N/A N/A 29.2 (12.7) N/A N/A N/A 
LEDD (mg):  
mean (SD)  
N/A N/A 583.5 (399.6)                                                                                                                                                                                                                                                                                                     N/A N/A N/A 
MoCA Score:  
mean (SD) 
27.9 (2.3) 26.1 (2.9) 25.2 (3.9) 0.0004 0.39 0.04 
Cube-root of WML 
volume (mm):  mean (SD) 
1.26 (0.83) 2.11 (0.72) 1.80 (0.95) 0.008 0.19 0.001 
  





Table 2: Analysis of variance for the impact of cognitive deficit (MoCA score), medication (LEDD 610 










Figure Captions 621 
Figure 1: Location of the regions of interest 622 
Figure 2: Mean images of K
trans
 and vp for each group 623 
Images of the mean contrast agent transfer coefficient K
trans
 and the plasma volume vp for each group. 624 
Individual images were first normalised to MNI space before averaging. A T1-weighted image is 625 
shown for reference.  626 
Figure 3: Regions of higher K
trans
 in the PD group compared to the CN group 627 
t-statistic map overlaid on structural image showing the regions of significantly higher K
trans
 in the 628 
PD group than in the CN group. Map is thresholded with voxel-level p < 0.001 (uncorrected) and  629 
minimum cluster size of 50 voxels. The arrow indicates the cluster that survives cluster-level family-630 
wise error correction for multiple comparisons (p<0.05).  631 
Figure 4: Mean values for K
trans
 and vp in regions of interest for each group 632 
Mean values are given for the (A) the contrast agent transfer coefficient K
trans
 and (B) the plasma 633 
volume vp. Error bars show the standard error in the mean. The significance of post-hoc t-tests 634 
(uncorrected) between K
trans
 in the PD and CN group are shown. SN = substantia nigra, CA= caudate, 635 
PU = putamen, P = pallidum, WML = white matter lesions, NAWM = normal-appearing white 636 






Vp as dependent 
variable 
 Deg. freedom F value P value F value P value 
Region 6 0.3 1.0 3.5 0.002 
MoCA 1 3.8 0.06 0.4 0.52 
LEDD 1 0.4 0.5 6.1 0.02 
UPDRS 1 0.5 0.5 0.02 0.9 
Region:MoCA 6 0.1 1.0 1.7 0.1 
Region:LEDD 6 0.5 0.8 1.0 0.4 
Region: UPDRS 6 0.4 0.9 0.8 0.5 
 
Figure 1: Location of the regions of interest 
 
 
Figure 2: Mean images of Ktrans and vp for each group 
Images of the mean contrast agent transfer coefficient Ktrans and the plasma volume vp for each 
group. Individual images were first normalised to MNI space before averaging. A T1-weighted image 
is shown for reference.  
 
Figure 3: Regions of higher Ktrans in the PD group compared to the CN group 
t-statistic map overlaid on structural image showing the regions of significantly higher Ktrans in the PD 
group than in the CN group. Map is thresholded with voxel-level p < 0.001 (uncorrected) and  
minimum cluster size of 50 voxels. The arrow indicates the cluster that survives cluster-level family-
wise error correction for multiple comparisons (p<0.05).  
 
Figure 4: Mean values for Ktrans and vp in regions of interest for each group 
Mean values are given for the (A) the contrast agent transfer coefficient Ktrans and (B) the plasma 
volume vp. Error bars show the standard error in the mean. The significance of post-hoc t-tests 
(uncorrected) between Ktrans in the PD and CN group are shown. SN = substantia nigra, CA= caudate, 
PU = putamen, P = pallidum, WML = white matter lesions, NAWM = normal-appearing white matter, 
FC = frontal cortex, PC = posterior cortices 
Supplementary Material 
 
1. Methods  
Further detail of MRI acquisition protocol and analysis is outlined below. 
1.1 MRI acquisition protocol 
 
A DCE-MRI dynamic series of 3D T1-fast  field echo (T1-FFE) were acquired with the 
following scan parameters: Field of view 192 mm x 192 mm and matrix size of 128 giving 
in-plane resolution of 1.5 x 1.5 mm; 32 contiguous axial slices of 4 mm thickness; echo time 
(TE) = 0.8 ms, repetition time (TR) = 2.4 ms, flip angle 10 degrees and image acquisition 
time of 7.6 seconds. 160 images were acquired over approximately 20 minutes.  
Prior to the dynamic scan, a series of additional 3D T1-FFE images were acquired at 3 flip 
angles (2, 5 and 10 degrees) in order to calculate a pre-contrast T1 map using the variable flip 
angle method (1), with geometry and all other parameters matched to the dynamic series, 
except only 8 image repeats were collected (from which a mean image was created), giving 
an acquisition time of 60 s per flip angle. In order to correct for B1 field inhomogeneities, a 
B1 mapping sequence (2) was also acquired with the same voxel size and coverage as for the 
variable flip angle images.  This consisted of a pair of 3D spoiled gradient echo images with 
TR1 = 25 ms and TR2 = 125 ms, flip angle 60 degrees, TE = 5 ms, acquisition time 117 
seconds.  
In addition, a T2-weighted FLAIR image was acquired with the following parameters: TR = 
10 s, inversion time 2.75 s, TE = 140 ms, in-plane resolution of 0.69 mm x 0.69 mm, and 100 
contiguous axial slices of 1.3 mm thickness with an acquisition time of 450 seconds. A 3D 
T1-weighted image was also collected with scan parameters: TR = 8.4 ms, TE = 3.9 ms, flip 
angle 8 degrees. Images were reconstructed with a resolution of 0.94 mm x 0.94 mm x 1mm, 
acquisition time 311 seconds.  
 
1.2 MRI analysis 
A voxel-by-voxel fit of the dynamic data for both the contrast agent transfer coefficient 
(K
trans






               [1] 
Where Ct(t) is the tissue concentration of the contrast agent and Cp(t) is the plasma 
concentration at time t after contrast agent injection at t=0.                      
The tissue concentration Ct(t) is calculated from the signal in the dynamic images St(t) 




                   [2] 
Where R1(t) is calculated from St(t) as described subsequently in equation 5.  Where r1 is the 




. R10 is the 
baseline longitudinal relaxation rate, taken from the pre-contrast T1 map using R10 = 1/T10. 
This pre-contrast T1 map was calculated by fitting the variable flip angle images on a voxel-








               [3] 
In order to correct for inaccuracies in the specified flip angles, θS, due to B1 inhomogeneities, 
the ratio of the image intensities in the B1 mapping sequence (r) was used to estimate the true 





) ⁡      where n=TR1/TR2.     [4] 
The deviation of the true flip angle from the specified flip angle (θS) is given by θT/θS and θ 
in equation [3] is multiplied by this factor on a voxel wise basis when calculating T1.  Prior to 
multiplication, the θT/θS image was smoothed using a convolution kernel of 3 voxels. 
R1(t) was calculated using equation [5] below, derived from equation [3], considering St as 
the signal in the post-contrast dynamic images and S0 as the mean signal from 5 pre-contrast 













]        where B=exp(-R10.TR). [5] 
 
Finally, the plasma concentration Cp(t), is derived from the blood concentration Cb(t)  which 
is also calculated using equations [2] and [5] with St the mean signal from the sagittal sinus 
region, S0 the mean signal from 5 pre-contrast dynamics within this region (again, neglecting 
the first one to avoid inflow effects), and T10 equal to the mean pre-contrast T1 from the 
sagittal sinus region. Cp(t) is derived from the measured blood concentration by correcting for 
hematocrit according to: Cp(t) = Cb(t)/ (1-Hct) where Hct of 0.40 was used for a female and 
0.45 for male (4).  
Equation [1] was then fit to Ct(t) and Cp(t) using constrained least squares minimisation 
(lsqcurvefit in Matlab) on a voxel-wise basis for 3 parameters: K
trans
, vp and T0, where T0 is 
the offset time between Ct(t) and Cp(t). K
trans





, vp between 0 and (1-Hct) and T0 between -20 and 20 s The non-zero lower bound 
on K
trans
, while un-physiological, is to avoid positive bias in the K
trans
 values which may in 
reality be very close to zero in healthy tissue. The negative bounds on T0 are to allow for the 
possibility that the peak sagittal sinus signal may occur earlier than that of the regional blood 
circulation if blood takes a particularly tortuous path to the region. In order to avoid local 
minima, minimisation was performed twice, using the fitted parameters of the first 
minimisation as starting parameters for the second minimisation, except for one parameter 
which was kept as the original value.  
Voxel-wise analysis was performed using the SPM12 PET toolbox to determine regional 
differences in K
trans
 and vp between the groups. First we co-registered the K
trans
 and vp maps to 
the high resolution 3D T1-weighted image: the first volume of the motion-corrected DCE 
series was used to compute the registration parameters which were then applied to the other 
images. Each T1-weighted image was segmented into tissue classes using SPM and grey and 
white matter masks were defined using a probability threshold of 75%. The co-registered 
parameter maps were masked to include signal only from grey and white matter. The T1-
weighted images were then normalized to Montreal Neurological Institute (MNI) space and 
the transformation applied to the K
trans
 and vp maps.  
1.3 Visual inspection of data quality 
The DCE concentration time course in the white matter and the sagittal sinus regions (i.e. the 
VIF) were extracted for each person in order to consider individual differences in this raw 
data prior to fitting. For example, attention was paid to the shape and amplitude of the VIF in 
order to ascertain that the contrast agent injection was as expected.  
Figure S1 shows example tissue concentration time courses for a representative person from 
each group, selected according to their K
trans
 and vp values being close to the median for the 
group. It can be seen that, while the vascular input functions are very similar (Figure S1A), 
the tissue curves begin to diverge, particularly for the PD group (Figure S1B). Baseline T1 
values did not vary significantly between the groups, with mean ± SE values of CN: 1.70 s ± 
0.04 s, CP: 1.76 s ± 0.04 s, PD: 1.74 s ± 0.04 s.  
 
Figure S1: Concentration time-course of contrast agent in blood and tissue  
Typical time-courses of the vascular input function (A) and the white matter contrast agent 
concentration (B) taken from representative subjects of each group. Subjects were selected 
according to K
trans
 and vp values being close to the median for the group. 
 
2. Results 
2.1 Voxel-wise analysis 
Tables S1, S2,S3, S4 and S5 provide details of the regions showing group differences in the 
voxel-wise analysis, highlighting regions of significant difference in K
trans
  between the PD 
and CN groups (Table S1), the PD and CP groups (Table S2) and the CP and CN groups 
(Table S3) and regional differences in vp between the CP and CN groups (Table S4) and CP 
and PD groups (Table S5). 
 
Table S1. Regions of significantly higher K
trans 
in the PD group than in the CN group. The t-












White matter in the R 
hemisphere precuneus 
extending into parietal 
lobe and calcarine 
 










22 -56 32 
32 -40 22 
28 -36 28 
16 -50 10 
12 -32 30 
White matter in the L 
and R precuneus 
extending into 
paracentral lobule 










-6 -40 64 
12 -36 60 
  8 -36 66 
-12 -28 52 
-12 -38 60 
R inf temporal gyrus  82 0.7 3.7 0.0001 50 -26 -26 
 
Table S2. Regions of significantly higher K
trans 
in the PD group than in the CP group. The t-
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Table S3. Regions of significantly higher K
trans 
in the CP group than in the CN group. The t-
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Table S4. Regions of significantly lower vp in the CP group than in the CN group. The t-
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Table S5. Regions of significantly lower vp in the CP group than in the PD group. The t-
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2.2 ROI analysis with scanner and gender matching 
To check that any apparent group differences in imaging metrics were not driven by group 
differences in gender or scanner used, we repeated the ROI analysis on a selected group of 
participants with these factors matched across groups.  
 
2.21 ROI analysis with scanner matching 
Table S6 demonstrates the demographics for participants whose data was collected on the 
same scanner at the Manchester Clinical Research Facility. Figure S2 shows regional values 
for K
trans 
and vp using data collected from these groups. The results are in broad agreement 
with the results reported in the main paper (Figure 4). ANOVA with K
trans
 as the dependent 
variable and WML volume, age and gender included as covariates showed a significant effect 
of group (F = 3.5, p=0.04) and region (F = 44.6, p<0.0001) on K
trans
 and no significant effect 
of WML volume (F=0.4, p=0.5), age (F=0.4, p=0.5) or gender (F=0.001, p=1.0). Post-hoc 
tests again showed K
trans
 to be significantly higher in PD than in CN (p=0.03, Bonferroni 
corrected) and no significant differences between the other two pairwise comparisons. 
Similar analysis with vp as the dependent variable showed a significant effect of region (F = 
55.2, p<0.0001) but not group (F = 0.9, p=0.4) on vp and no significant effect of WML 
volume (F=0.02, p=0.9), age (F=1.6, p=0.2) or gender (F=0.05, p=0.8). 
  
Table S6: Demographics and clinical and radiological characteristics of the participants for 
data collected only on the same scanner 
 
CN: control negative; CP: control positive; FH of CVD: family history of cardiovascular disease; LEDD: levodopa equivalent 
daily dose; MoCA: Montreal Cognitive Assessment; PD: Parkinson’s disease; UPDRS 111: unified Parkinson’s disease rating 
scale motor score; WML: white matter lesion. 
 
 
CN (n=20) CP (n=15) PD (n=36) p value  
PD v CN 
p value  
PD v CP 
p value  
CP v CN 
n (F:M) 13:7 4:11 12:37 0.002 0.26 0.02 
Age (years):  
mean (range) 
67.8 (51-81) 69.1 (53-84) 70 (52-85) 0.31 0.69 0.64 
No. of cardiovascular 
risk factors: mean (SD) 
1.71 (1.31) 2.93 (1.16) 1.72 (1.52) 0.92 0.009 0.006 
Cardiovascular  Risk 
Factors  (% of group): 
Hypertension 
Diabetes mellitus  
FH of CVD 
Smoker 
Hypercholesterolaemia  

























































(years): mean (SD) 
N/A 1.1 (0.77) 6.9 (4.38) N/A N/A N/A 
Hoehn & Yahr Score:  
mean (SD) 
N/A N/A 2.61 (0.95) N/A N/A N/A 
UPDRS Score: 
mean (SD) 
N/A N/A 30.4 (11.6) N/A N/A N/A 
LEDD (mg):  
mean (SD)  
N/A N/A 577.5  (329.2)                                                                                                                                                                                                                                                                                                 N/A N/A N/A 
MoCA Score:  
mean (SD) 
27.7 (2.0) 26.1 (2.9) 24.9 (4.1) 0.001 0.22 0.08 
Cube-root of WML 
volume (mm):  mean 
(SD) 
1.37 (0.93) 2.11 (0.72) 2.08 (0.91) 0.009 0.89 0.01 
 
Figure S2: Mean group values for K
trans
 and vp in regions of interest from data collected 
on the same scanner 
Mean values are given for the (A) the contrast agent transfer coefficient K
trans
 and (B) the 
plasma volume vp. Error bars show the standard error in the mean. SN = substantia nigra, 
CA= caudate, PU = putamen, P = pallidum, WML = white matter lesions, NAWM = normal-
appearing white matter, FC = frontal cortex, PC = posterior cortices. 
2.22 ROI analysis with gender matching 
Table S7 shows the demographics and clinical characteristics of the gender matched groups. 
Figure S3 show regional values for K
trans 
and vp using data from these groups. The results are 
in broad agreement with the results reported in the main paper (Figure 4). ANOVA with K
trans
 
as the dependent variable and WML volume, age and gender included as covariates showed a 
significant effect of group (F = 3.0, p=0.05) and region (F = 51.1, p<0.0001) on K
trans
 and no 
significant effect of WML volume (F=0.04, p=0.8), age (F=2.2, p=0.14) or gender (F=0.1, 
p=0.7). Post-hoc tests again showed K
trans
 to be significantly higher in PD than in CN 
(p=0.04, Bonferroni corrected) and no significant differences between the other two pairwise 
comparisons. Similar analysis with vp as the dependent variable showed a significant effect of 
region (F = 88.1, p<0.0001) but not group (F = 0.8, p=0.5) on vp and no significant effect of 
WML volume (F=0.01, p=0.9), age (F=1.0, p=0.3) or gender (F=0.5, p=0.5). 
 
Table S7: Demographics and clinical and radiological characteristics of the gender matched 
study group  
 
CN: control negative; CP: control positive; FH of CVD: family history of cardiovascular disease; LEDD: levodopa equivalent 
daily dose; MoCA: Montreal Cognitive Assessment; PD: Parkinson’s disease; UPDRS 111: unified Parkinson’s disease rating 
scale motor score; WML: white matter lesion 
 
 
CN (n=21) CP (n=15) PD (n=49) p value  
PD v CN 
p value  
PD v CP 
p value  
CP v CN 
n (F:M) 6:15 4:11 12:37 0.20 0.25 0.29 
Age (years):  
mean (range) 
67.1 (52-81) 69.1 (53-84) 68.9 (52-85) 0.42 0.84 0.44 
No. of cardiovascular 
risk factors: mean (SD) 
1.71 (1.31) 2.93 (1.16) 1.72 (1.52) 0.97 0.002 0.003 
Cardiovascular  Risk 
Factors  (% of group): 
Hypertension 
Diabetes mellitus  
FH of CVD 
Smoker 
Hypercholesterolaemia  

























































(years): mean (SD) 
N/A 1.1  (0.77) 7.2 (4.45) N/A N/A N/A 
Hoehn & Yahr Score:  
mean (SD) 
N/A N/A 2.60 (0.09) N/A N/A N/A 
UPDRS Score: 
mean (SD) 
N/A N/A 29.2 (12.7) N/A N/A N/A 
LEDD (mg):  
mean (SD)  
N/A N/A 583.5 (399.6)                                                                                                                                                                                                                                                                                                     N/A N/A N/A 
MoCA Score:  
mean (SD) 
27.7 (2.4) 26.1 (2.9) 25.3 (3.9) 0.004 0.39 0.10 
Cube-root of WML 
volume (mm):  mean 
(SD) 
1.26 (0.81) 2.11 (0.72) 1.80 (0.95) 0.02 0.19 0.002 
 
Figure S3: Mean group values for K
trans
 and vp in regions of interest with matched 
gender balance between groups 
Mean values are given for the (A) the contrast agent transfer coefficient K
trans
 and (B) the 
plasma volume vp. Error bars show the standard error in the mean. SN = substantia nigra, 
CA= caudate, PU = putamen, P = pallidum, WML = white matter lesions, NAWM = normal-
appearing white matter, FC = frontal cortex, PC = posterior cortices. 
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